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IN THE SUPREME COURT
OF THE STATE OF CALIFORNIA
PDX, INC. & NATIONAL HEALTH INFORMATION
NETWORK, INC.,
Defendants and Appellants,
vs.

KATHLEEN HARDIN and DANE HARDIN,
PlaintiffS and Respondents.

REAL PARTIES IN INTEREST'S
ANSWER TO DEFENDANTS/APPELLANTS PDX, INC. &
NATIONAL HEALTH INFORMATION NETWORK, INC.'S
PETITION FOR REVIEW

INTRODUCTION: WHY REVIEW SHOULD BE DENIED
Petitioners PDX, Inc. and National Health Infonnation Network, Inc.
(collectively "PDX") ignore the record and the Court of Appeal's statement
of the issues and facts in contending that the decision burdens First
Amendment speech. That is not the case. The Court of Appeal decision
does not allow for liability for truthful statements in public records. This
case involves PDX's conduct, the intentional modification of its software
so that Safeway could distribute patient drug education monographs that
excluded warnings, conduct that PDX knew would pose a risk ofhann to
consumers.
Nonetheless, PDX seeks review contending that the Court of Appeal
decision is unprecedented and inconsistent with First Amendment
principles. PDX's First Amendment arguments are premised on the factual
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misstatement that the monograph was a truthful statement based on public
records. There is no dispute that the monograph given to Mrs. Hardin
omitted FDA-mandated black box warnings about life threatening risks of
taking Lamotrigine.
In its decision under the anti-SLAPP statute, the Court of Appeal did
not decide whether PDX' s conduct was in furtherance of the exercise ofthe
constitutional right of petition or free speech.
The Court of Appeal's decision rests on the second prong of the antiSLAPP statute, whether plaintiffs showed a probability of prevailing on the
merits. PDX never attempted to defend the reasonableness of its conduct in
the court below. Its primary argument in the Court of Appeal was that it
owed no duty to ]Vtts. Hardin as a matter oflaw. In rejecting these
contentions, the Court of Appeal applied the law of negligence in line with
established prccedent. The Court of Appeal conducted an independent
review of the record to determine under the anti-SLAPP statute that the
evidence presented was sufficient to support a favorable judgment. As
such, Plaintiffs' negligence and products liability claims withstood PDX's
anti-SLAPP motion.
PDX further contends that the Court of Appeal erred when it found
PDX assumed a duty of care and contends that the opinion is, therefore, in
conflict with Rivera v. First Databank, Inc. (2010) 187 Cal.App.4th 709, on
which PDX relied for the contention that it owed no duty to Mrs. Hardin as
a matter oflaw. PDX's assertions fail on several grounds. First, PDX
essentially seeks review for determinations as to controlling factual issues
that may not be decided at the pleading stage. As noted by the Court of
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Appeal, factual issues such as those raised by PDX go to whether PDX
acted with due care, and are not relevant to finding whether PDX assumed a
duty under California law. Second, PDX ignores the distinctions made by
the Court of Appeal between this case and Rivera, distinctions that were
based on evidence in this case. The Court of Appeal explained that, unlike
in Rivera, there was in this case an FDA-required black box warning that
applied to all consumers, and it was omitted. PDX knew - and even told
Safeway - that warnings were required to avoid injury to consumers.
Nonetheless, PDX entered into a contract with Safeway in 2006 to modifY
its software so that abbreviated monographs without important warnings
would be given to Safeway customers. Review of these controlling factual
determinations at this stage would be premature. An anti-SLAPP motion is
decided at the pleading stage prior to discovery, not after full discovery, as
with a motion for summary judgment.
PDX petitions for review on the additional grounds that it is
insulated from liability pursuant to Section 230 of the Communications
Decency Act This argument does not warrant review because the Court of
Appeal found, based on relevant law and the evidence in this case, that
Section 230 does not immunize PDX. The Court of Appeal correctly
found, based on the evidence, that Plaintiffs' claims do not arise from
PDX's role as a distributer of information that was furnished by another
content provider.
Finally, there is no concern that courts in the future would
interpret this decision as allowing liability for truthful statements about
public records because the Court of Appeal's decision hinges on the
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evidence in this case and makes narrow findings. Review would be
unnecessary and premature.
STATEMENT OF THE CASE I
A.

PDX provided software that assembles and prints patient
educatio_n monographs.
PDX is "'an independent provider of software that distributes drug

infonnation to phannacy customers'" including patient drug edncation
monographs ("monographs"). (Op. at 2.) The monographs are authored by
third parties, in this case Wolters Kluwer Health, Inc. ("WKH"), an
independent publisher of patient education drug monographs and are
summaries of infonnation from package inserts and medication guides
"written in lay language for consumers" to supplement oral counseling
received when a prescription is filled. (Op. at 2 & 3 [referencing generally
Rivera v. First Databank, Inc. (2010) 187 Cal.App.4th 709,713 (Rivera)].)

Based on the record, the Court of Appeal found that there was no factual
dispute as to the nature ofPDX's activity. (Op. at 2.)
PDX has a licensing agreement with WKH to obtain and provide the
infonnation in monographs through its software, enabling phannacies to
print and distribute monographs when a prescription is filled. (Op. at 3.)
According to PDX, the purpose ofthe monograph is to provide patients
useful, accurate and comprehensive infonnation about thcir prescription
I Real parties in interest agree with the facts stated in the Court of
Appeal's opinion. We summarize those facts and supplement with
additional facts from the record.
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drug, including waruings of known health risks associated with the drug. (3
C.T. 719 [Loy Decl. 'll9].)
PDX had a license agreement with Safeway, Inc. ("Safeway") to
provide its software for use by Safeway in its pharmacies. (3 C.T. 717; Op.
at 2-3.) Under this agreement, Safeway paid PDX in excess of$l million
every year in license and maintenance fees for 605 Safeway pharmacies in
the U.S. and Canada. (3 C.T. 725-737.) Using the PDX software, Safeway

automatically prints monographs, which are attached to a label with the
patient's personal information. (3 C.T. 688 [Safeway Person Most
Knowledgeable Depo. ("PMK Depo") 26: 13-23][emphasis added].)
Safeway considers the monograph to be part of the label. (3 C.T. 686 [PMK
Depo.20:11-21].)
B.

The Industry staved off mandatory FDA regUlation of patient
drug information by adopting an industry "Action Plan."
In 1996, Congress enacted Public Law 104-180, which was an

industry-supported alternative to the FDA's proposed regulations that
would have required a regulatory approval process for drug infonnation
sheets or monographs. (3 C.T. 776; Op. at 2.)
P.L. 104-180 required that "health care professionals, consumer
organizations, voluntary health agencies, the pharmaceutical industry, drug
wholesalers, [and] patient drug information database companies" develop a
plan:
to ensure the transmittal of useful information
to the consuming public, including being
scientifically accurate, non-promotional in tone
and content, sufficiently specific and
comprehensive as to adequately inform
consumers about the use of the product, and in
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an understandable, legible format that is readily
comprehensible and not confusing to consumers
expected to use the product. (3 C.T. 770. 110
Stat. 1593 [Aug. 6.1996].)
Under P.L. 104-180, the FDA could not enact mandatory regulations
of consumer drug information ifthe industry came up with its own "Action
Plan" to address the problem of inadequate drug information to consumers.
(3 C.T. 776.)
In 1996, drug product information producers (including WKH),
pharmacists, physicians, phannaceuticalcompanies, industry associations
and consumer advocates collaborated on a "private sector initiative aimed
at preventing further FDA regulation" by ensuring that the companies met
the goals ofP.L. 104-180. (3 C.T. 741, 813-819; SAA 055.) The industry
committee issued its "Action Plan for the Provision of Useful Prescription
Medicine Information" ("Action Plan" or "Keystone Criteria") in
December 1996. (3 CT 767-822.) The Secretary of Health and Human
Services approved the Action Plan in January 1997. (3 C.T. 762; Op. at 2.)
"The goals [ofthe Keystone Criteria] were to improve the quality of
information, and thereby reduce injury." (3 C.T. 719 [Loy Dec!.
~

9][emphasis added].) '''The purpose of this Action Plan is to improve the

quality and availability of useful information that is voluntarily provided to
consumers with their prescription medicines. The rationale for the Plan is
that providing consumers with useful information about their prescription
medicines can reduce the risk of preventable, medication-induced injury
and improve health outcomes.'" (Op. at 2 [quoting the Action Plan].) The
Action Plan defined useful information as "'that which is sufficiently
comprehensive and communicated such that consumers can make informed
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decisions about how to receive the most benefit from medicines and protect
themselves from harm. Both the substance and presentation of the
information are important. '" (ld.)
Prior to 2005, PDX software permitted retailers, including Safeway,
to print abbreviated (five-section) or complete (eight-section) versions of
the drug monograph for a given drug. (Op. at 3.) The five-section
monographs excluded three sections: "Before Using This Medicine",
"Overdose" and "Additional Information." (3 C.T. 718 [Loy Dec!. '1[7]; Op.
at 3.) The excluded section "Before Using This Medicine" contained
warnings as to known serious risks from the prescription drug. (ld.)
In 2005, PDX revised its software program to prevent retailers,
including Safeway, from printing abbreviated drug monographs. (3 C.T.
719 [Loy Dec!.

,r 12]; Op. at 3.)

Benjamin Loy, Senior Vice President of

Industry Relations for PDX, Inc. and National Health Information Network,
Inc. stated that '''[t]his software revision was made in response to both
regulatory guidelines for the provision of patient education information and
an internal recommendation by Jim Boyd, R.Ph., then Sr. Vice President
[ofJ Network Services NHlN. '" (Op. at 4-5 [quoting the trial court's
ruling].)

C.

PDX intentionally modified its software to permit Safeway to
provide abbreviated monographs.
In 2006, after PDX made printing all eight-sections mandatory, "'a

Safeway representative contacted PDX because it wanted to use the five
section monograph, rather than the eight section monograph with the
warnings at issue here.'" (ld.) Thus, in 2006, PDX and Safeway entered
Kathleen Hardin's and Dane Hardin's
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into a written agreement in which PDX agreed to provide '''[p]rogramming
to allow the system to provide the five section monograph ... '" after PDX
"obtained a release ofliability and indemnity from Safeway." (Op. at 3 & 5
[emphasis added].)
In the 2006 agreement with Safeway, PDX acknowledged "that
providing the full eight-section version would better enable patients to 'use
the medication properly and appropriately, receive the maximum benefit,
and avoid harm. '" (Op. at 11 [quoting the 2006 agreement with Safeway]
[emphasis added].)

D.

Kathleen Hardin was given a five-section monograph that
omitted necessary warnings.
Plaintiff Kathleen Hardin suffered complete blindness, as well as

pennanent, severe and painful scarring as a result of Stevens-Johnson
Syndrome ("SIS") and Toxic Epidennal Necrolysis ("TEN") caused by
2

taking Lamotrigine, the generic form ofLamicta1. (Op. at 1.) Plaintiff
later leamed that Lamotrigine carries a significant risk of SIS and TEN.
(Op. at 1.)
Since 1994, the FDA has required "boxed warnings" about the
possibility of "life threatening rashes" caused by Lamictal. (1 C.T. 40 [Loy
Dec!.

~

11].) Also called "black box warnings," this is the strongest

waming that the FDA requires and signifies that medical studies indicate

Lamotrigine is the generic form ofLamicta!. The names are used
interchangeably throughout this answer.
2
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that the drug carries a significant risk of serious or even life-threatening
adverse effects. (21 C.F.R. § 201.57 (c)(1).)
Mrs. Hardin filled her prescription for Lamictal at a Safeway
pharmacy. (Op. at 3.) The abbreviated monograph was the only product
information she received with her prescription and was the only
infonnation she read and considered in deciding to take Lamictal. (Op. at

3.) The monograph was attached to a label with her personal information.
(3 C.T. 664, 667.)
The abbreviated monograph provided to Mrs. Hardin excluded the
"Black Box" warnings that were contained in the section "Before Using
This Medicine," which was one of the sections omitted from the fivesection Lamotrigine monograph that WKr-r provided to PDX. The omitted
warning stated:
WARNING: SERIOUS AND SOMETIMES FATAL
RASHES HAVB OCCURRED RARELY WITH THE
USE OF THIS MEDICINE .... Contact your doctor
immediately if you develop rash symptoms, including
red, swollen, blistered, or peeling skin. Treatment with
this medicine should be stopped unless it is clearly
determined that the medicine did not cause the rash.
Even ifthe medicine is stopped, a rash caused by this
medicine may still become life threatening or cause
serious side effects (such as pennanent scarring.) (Op.
at 3-4.)

If Mrs. Hardin had been given the warning of serious and sometimes
fatal rashes, she would have read it and would not have taken the
medication. (Op. at 4.)
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E.

The trial court denied PDX's anti-SLAPP motion to strike.

Kathleen Hardin and her husband sued her physician, the generic
drug company that manufactured and distributed Lamotrigine, Safeway,
Inc., WKH and Doe Defendants. (Op. at 1-2.) WKH filed a motion to
strike Mrs. Hardin's claims under Code of Civil Procedure section 425.16
(the "anti-SLAPP" statute). (Op. at 4.) WKH asserted that Plaintiffs'
negligence and products liability claims against it arose from WKH's
"protected speech concerning a public issue or an issue of public interest."
(Op. at 1 & 4.) Attached to WKH's motion was a complete eight-section
Lamotrigine monograph that included the section titled "Before Using This
Medicine." (3 C.T. 674-678.) The trial court granted WKI-['s motion to
strike and ruled that "WKH's production of drug monographs was
protected speech under section 425.16, subdivision (e)(4)." As to the
second prong, the trial court ruled that Plaintiffs "had no probability of
prevailing on her claims because, following the rationale of Rivera, supra,
187 Cal.App.4th 709, she could not establish that WKH owed her any
duty." (Op. at 4.)
Plaintiffs amended their complaint to allege causes of action for
negligence and products liability against PDX. (Op. at 4.) PDX filed an
anti-SLAPP motion to strike and argued that the claims against it were
identical to those brought against WKH and should be dismissed for the
same reasons. (Op. at 4.) "The trial court disagreed" and found that the
"activity underlying PDX's alleged liability was the reprogramming of its
software to permit Safeway to give customers an abbreviated, five-section
monograph that omitted warnings about SJS instead of the full eight-section
Kathleen Hardin's and Dane Hardin's
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version that included those warnings." (Op. at 4.) The trial court
concluded: "'Plaintiffs have asserted acts by PDX that go beyond mere
distribution of the WKH's monographs'" and "that PDX's reprogramming
activities were not acts in furtherance of the defendant's right of petition or
free speech within the meaning of section 425.16 and denied PDX's motion
to strike." (Op. at 4 & 5.) PDX appealed the trial court's ruling.

F.

The Court of Appeal affirmed the trial court's ruling denying
PDX's Anti-Slapp Motion to Strike.
The Court of Appeal in a unanimous decision affIrmed the trial

court's ruling, finding that the trial court had not erred in denying PDX's
anti-SLAPP motion to strike "because the plaintiff demonstrated a
probability she may prevail on her claim." (Op. at 1.)
The Court of Appeal noted that the trial court had denied the antiSLAPP motion on the first prong, ruling that "PDX's role in the production
and dissemination ofthe short-fonn monograph Hardin received was not
'conduct in furtherance of the exercise of the constitutional right of petition
or the constitutional right of free speech ... '" (Op. at 7.) The Court of
Appeal detennined that it "need not answer this interesting question, for,

assuming arguendo that Hardin's claims against PDX arose from protected
first amendment activity,

if credited at trial her evidence would be

sufficient to support afavorablejudgment." (Op. at 7 [emphasis added].)
Thus, the Court of Appeal reviewed the "trial court's detenninations as to

whether the plaintiff has shown a probability ofprevailing independently."
(Op. at 6-7 [citing ComputerXpress, Inc. v. Jackson (2001) 93 Cal. App. 4th
993,999] [emphasis added].)
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As noted by the Court of Appeal, in order to prevail on an antiSLAPP motion, a plaintiff need only provide '''evidence establishing a
prima facie case which, if believed by the trier of fact, will result in a
judgment for the plaintiff" and that the Court "'accept as true the evidence
favorable to the plaintiff [citation] and evaluate the defendant's evidence
only to determine if it has defeated that submitted by the plaintiff as a
matter oflaw. '" (Op. at 7 [quoting Nygard, Inc. v. Uusi-Kertyla (2008) 159
Cal.App.4th 1027, 1036].) The Court of Appeal further noted that the
"burden placed on the plaintiff must be compatible with the early stage at
which the motion is brought and heard [citation] and the limited
opportunity to conduct discovery." (Id. [quoting Wilcox v. Superior Court
(1994) 27 Cal.App.4th 809,823].) "[O]nly a minimal showing of merit is
required." (Id. [quoting Yu v. Signet Bank/Virginia (2002) 103 Cal.App.4th
298,318].)
The Court of Appeal held that the record in this case "sufficiently
makes out a claim that PDX assumed a duty of care by undertaking to
render services to Safeway 'of a kind [it] should have recognized as
necessary for the protection of third persons ... " (Op. at 11.)
The Court of Appeal in so finding determined that Rivera did not
control for several reasons. (Op. at 8.) First, the "evidentiary shortcomings
presented in Rivera are not present here." (Op. at 8-9.) In Rivera, plaintiff
provided no evidence to support the allegation that the monograph excluded
a black box warning, or that the black box warning would have applied to
the plaintiff in that case. In this case, the evidence shows that a black box
warning existed, that it was intentionally excluded from the monograph
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Plaintiff received and that it would have applied to all consumers of the
drug. (Id.)
Second, Rivera did not consider, as alleged in this case, the negligent
undertaking doctrine. The Court of Appeal cited section 324A of the
Restatement (Second) of Torts, which provides, in part: '''One who
undertakes ... to render services to another for which he should recognize
as necessary for the protection of a third person of his things, is subject to
liability to the third person for physical hann resulting from his failure to
exercise reasonable care to [perform] his undertaking ... '" (Op. at 9.) The
Court set forth the requirements under section 324A and cases applying
section 324A, inciudingArtiglio v. Corning, Inc. (1998) 18 Ca1.4th 604.
(Op. at 10.) The Court then held that "PDX knew that enabling Safeway to

print the abbreviated monograph could place patients at risk ... " (Op. at
10.) The evidence in support of this included, among other things, the 2006
agreement between Safeway and PDX that specifically noted that the
complete eight-section monograph would "better enable patients to 'use the
medication properly and appropriately, receive the maximum benefit, and
avoid hann. '" (Op. at 11.) Based on this record, the Court of Appeal found
that PDX had assumed a duty of care. (Op. at II.)
Third, the Court of Appeal rejected the contention that PDX had no
duty on the grounds that the monograph L'1dicated "it did not cover all
possible adverse effects aod advised patients to read the medication guide .
. ." (Op. at 11.) This disciaimerwas irrelevant to the scope ofPDX's duty.

(Id.) Instead, the Court of Appeal noted:
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The cited provisos and their foreseeable effect on
consumers are relevant to whether PDX acted with due
care when it enabled Safeway to omit warnings from
WKH monographs, but it is the nature ofPDX's
undertaking, not the care with which it was carried ont,
that determines whether it assnmed a duty nnder
section 324A in the first place.
(Op. at 1l.)
The Court of Appeal similarly rejected each ofPDX's
remaining arguments. The court rebutted the contention that section 230 of
the federal Communications Decency Act (47 U.S.C. § 230)("CDA)
"immunizes [PDX] from liability for providing electronic access" to
monographs. The Court of Appeal clarified that the claims do not arise
from PDX's role as a service provider enabling Safeway to access software.
(Op. at 12.) Instead, "Hardin sued PDX because it intentionally modified
its software to allow Safeway to distribute abbreviated drug monographs

that automatically omitted warnings of serious risks" and, as such, the
Court of Appeal affirmed that "'this is not a case in which a defendant
merely distributed information from a third party author or publisher. ""
(Op. at 12 [emphasis added].)
The Court of Appeal further addressed PDX's claims that the
First Amendment and Civil Code section 47( d) "immunize it from liability
for distributing what it describes as 'truthful summaries of the FDA's
Package Insert and Medication Guide.'" (Op. at 13.) The Court of Appeal
stated that "[i]t has not been established at this juncture that WKH's
monographs are 'truthful summaries' of official FDA proceedings" or that
"they qualifY as 'public journals''', or "that they 'do nothing to dilute' the
warnings in FDA-approved medication guides ... and are not otherwise
Kathleen Hardin's and Dane Hardin's
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misleading." (Op. at 13.) There is no evidence that monographs are not
misleading. PDX's evidence did not defeat evidence "submitted by Hardin
as a matter oflaw." (Op. at 13.)
PDX petitioned the Court of Appeal for rehearing on the
grounds that the Court of Appeal's opinion "did not resolve Plaintiffs'
products liability claim" and "misstated -and/or omitted a number of
material facts", including, according to PDX, the fact that the Action Plan
provides guidelines and does not carry the force of the law. (Pet. Reh., filed
7/7/14, 1.) PDX presented arguments similar to the arguments presented in

its petition for review. The petition for rehearing was denied. The Court of
Appeal held that "Hardin's theory is that PDX's software program, not the
information it produces, is the defective product. PDX has not argued, let
alone shown, that Hardin cannot prevail under that theory. Maybe so, but
at this early juncture we carmot so conclude." (Order, 7/21114.) The Court
of Appeal reaffirmed that "'[tJhe causes of action need only be shown to
have 'minimal merit.'" (Order, 7/21114.)

LEGAL DISCUSSION
I.

REVIEW IS NOT NECESSARY BECAUSE THE PETITION
FAILS TO PRESENT A FIRST AMENDMENT ISSUE BASED
ON THE RECORD IN THIS CASE.
PDX's First Amendment arguments are premised on the c1aim-

repeated throughout the petition - that the monograph was a "truthful
statement ... based on public records." (Pet. at 18.) That is a material
factual misstatement. As stated in the Court of Appeal, there is no dispute
that the monograph omitted the black box warning, the most important of
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all the warnings, as to "serious and sometimes fatal rashes." (Op. at 12.)
The logic ofPDX's arguments would permit an immunity for
misrepresentations.
Even further, in so arguing, PDX sets forth factual contentions,
based on the language of the monograph, and asks that this Court review
this case and the language of the monograph to make a determination as to
controlling facts as a matter of law. (Op. at 19.) Such review is
unnecessary and premature. The Court of Appeal stated that PDX's
evidence has not defeated that submitted by Plaintiffs as a matter of law.
(Op. at 13.) Factual issues must be developed in the trial court beyond the
pleading stage.
As to PDX's new argument that the First Amendment requires
"knowing falsity" for liability, PDX did not make that argument in the
Court of Appeal. (Pet. at 24.) The Supreme Court does not ordinarily
"consider an issue that the petition failed to timely raise in the comi of
appeal." (Cal. Rules of Court, rule 8.5000(c)(l).) In any cvent, the record
here was sufficient to establish knowing falsity because PDX "intentionally
modified its software to allow Safeway to distribute abbreviated drug
monographs" that excluded warnings that it knew were important to avoid
harm to consumers. (Op. at 11 & 12.)
While PDX's petition attempts to reframe the Comi of Appeal's
decision as premising liability on truthful statements, as the trial court
observed, PDX's conduct went "'beyond mere distribution of the WKH's
monographs'" and "that PDX's reprogramming activities were not acts in
furtherance of the defendant's right of petition or free speech within the
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meaning of section 425.16 ... " (Op. at 4 & 5.) The Court of Appeal did not
decide this issue. The Court of Appeal's decision rests on the second prong
of the anti-SLAPP statute and was an independent basis for affirming the
trial court ruling. To the extent that PDX may be asking this Court to
decide whether its conduct was somehow protected activity for the
purposes of the first prong of the anti-SLAPP statute, that issue is moot.
The Court of Appeal explicitly stated that it reviewed the
"probability of prevailing independently" and decided that it did not have to
answer the question raised by the first prong as the trial court did before it,
because it stated that, even "assuming arguendo that Hardin's claims
against PDX arose from protected first amendment activity,

if credited at

trial her evidence would be sufficient to support afavorable judgment."
(Op. at 7 [emphasis added].) While PDX now argues that this case presents
the First Amendment issue of liability for "truthful statements" ~ without
ever mentioning the anti-SLAPP statute ~ PDX ignores the evidence in the
case to the contrary and thatthe case arises out of its conduct.

II.

REVIEW SHOULD NOT BE GRANTED BECAUSE THE
FACTUAL RECORD IS INCOMPLETE AND THERE IS NO
CONFLICT OF LAW TO RESOL YE.
The Court of Appeal affirmed the denial ofPDX's anti-SLAPP

motion, which means the case returns to the trial court for discovery and
trial. Review of controlling factual issues at this time would be premature.
The Court of Appeal noted that "'the burden placed on the plaintiff must be
compatible with the early stage at which the motion is brought and heard
[citation] and the limited opportunity to conduct discovery. ", (Op. at 7
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[quoting Wilcox v. Superior Court (1994) 27 Cal.App.4th 809, 823,
disapproved on other ground in Equilon, supra, 29 Cal.4th at p. 68, fu. 5].)
Controlling factual issues must be developed at the trial court. Plaintiffs
met their burden at this stage. The standard required in evaluating the
causes of action, as well as the evidence in support thereof in the context of
the two-step process delineated in the anti-SLAPP statute is clearly set forth
in the Court of Appeal's decision. (Op. at 7.)
Nonetheless, PDX is requesting that detenninations be made as to
controlling facts at the pleading stage and prior to discovery. As to the
existence of a duty PDX owed to Plaintiff, PDX again bases its argument
on the same misstatement - that the monograph PDX produced is "truthful
consumer product infonnation." (Pet. at 26.) The Court of Appeal
addressed this point as stated hereinabove. PDX argues that there could be
no liability under a negligent undertaking theory because Mrs. Hardin's
injuries were not foreseeable. (Pet. at 36.) This argument flies in the face
ofthe evidence and the law as articulated by the Court of Appeal, including
the contract that PDX and Safeway entered into (contained in the record), in
which PDX expressly acknowledged that the complete monograph (which
included the black box warning) were necessary to comply with industry
standards and to "avoid harm" to consumers. (3 C.T. 762.)
PDX contends that certain facts, including that Safeway decided to
givc a five-section monograph, that the FDA re.quired a medication guide,
that PDX relied on others to provide warnings (for which there is no
evidence), and that the monograph referred to a medication guide (an
argument the Court of Appeal explicitly addressed in its opinion), warrant
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review by the Supreme Court as to PDX's liability under a theory of
negligent undertaking. (pet. at 7; Op. at 8.) However, PDX's arguments do
not make review necessary because the arguments are factual arguments
that go to whether or not PDX acted with due care or caused the injuries,
and do not show that the Court of Appeal's finding of whether it assumed a
duty under section 324A, was erroneous under the applicable law. (Op. at
11.) PDX seeks review to have its defenses prematurely evaluated and to
thereby make an anti-SLAPP motion, a motion at the pleadings stage which
precludes discovery, into a motion for summary judgment.
The Court of Appeal further properly addressed arguments ofthis
nature when it noted that it "disagreed with PDX's view that, as a matter of
law, this language had any bearing upon the scope of [PDX's] duty." (Op.
at 11.) Instead, the Court of Appeal determined that "the cited provisos and
their foreseeable effect on consumers are relevant to whether PDX acted
with due care when it enabled Safeway to omit warnings from WKH
monographs, but it is the nature ofP DX's undertaking, not the care with
which it was carried out, that determines whether it assumed a duty under
section 324A in the first place." (Op. at 11 [emphasis added].)

PDX further asserts that under Rivera, it had no duty. Rivera is not
persuasive authority in that it does not cite authority for, nor stand for the
proposition that, the producer of consumer drug information owes no duty
to consumers. Ba&ed on the Court of Appeal's decision, there is no conflict
oflaw as PDX suggests. (pet. at 8.) As the Court of Appeal explained,
Rivera is not controlling because "[u ]nlike Rivera, here there was evidence

that the black-box waming had been deleted from the monograph Hardin
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received with her prescription" and that it "would have applied to all
potential consumers ofLamotrigine." (Op. at 8-9.)
Finally, PDX's petition regarding the products liability theory is also
premature for the same reasons as stated above. Again, the Court of
Appeal in its opinion affirmed the denial of an anti-SLAPP motion to
strike, which means the case returns to the trial court for discovery and
trial. As the Court of Appeal stated, "at this early juncture we cannot
... conclude" that PDX has shown that it must prevail on the products
liability claim as a matter oflaw. (Op. at 20.)

m.

REVIEW IS NOT NECESSARY BECAUSE THE COURT OF
APPEAL CORRECTLY APPLIED SECTION 230 OF THE
COMMUNICATIONS DECENCY ACT TO THE INSTANT
CASE.
PDX argues that it is insulated from liability under Section 230 of.

the Communications Decency Act ("CDN'). The Court of Appeal decision
correctly stated that the claims in this case do not arise from PDX's role as
a software provider enabling Safeway to access the monograph. (Op. at
12.) The claims were bronght because PDX "intentionally modified its
software to allow Safeway to distribute abbreviated drug monographs .. ,"
which is conduct that is not immnnized by the CDA. (Jd.)
PDX inaptly analogizes its role to that of an internet website that
publishes content provided by others. But as the Court of Appeal explained,
PDX's conduct in contracting with Safeway to distribute monographs that
omitted important drug warnings takes this case out of the purview of
Section 230. '''One need look no further than the face of the statute to see
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why. The CDA only immunizes 'information provided by another
infonnation content provider.' (47 U.S.C. § 230 (c)(1).)" (Op. at 12.)

In addition to the reasons stated in the Court of Appeal decision,
Section 230 does not apply because Mrs. Hardin was not involved in any
way with obtaining information online. (Op. at 12.) As the Conrt of Appeal
noted, and as continues to be true, none ofthe cases upon whichPDX relied
or that PDX cited applied the CDA to a case such as the present one. (Op.
at 12.)
This is a case in which a recipient had no interaction with or
knowledge of any "interactive computer service." If PDX' s view were
adopted, the seller of a physical product that used an "interactive computer
service" to create the paper label could avoid the traditional seller's product
liability for failure to warn, or a publisher could download defamatory
information for a website, print it in a newspaper and deliver it to
newsstands - all without a traditional publisher's liability for defamatory
content. No case supports such an interpretation. In the information age,
almost all commerce can be traced back to one or more transactions over
the Internet. For that reason, to s11"etch the CDA to immunize PDX's
conduct in this case would lead to unintended and virtually limitless
immunity from tort liability.

CONCLUSION
PDX has provided no grounds for review by this court of the
decision affirming the den:ial ofPDX's anti-SLAPP motion to strike.
Review would be unwarranted and premature. Review at this time would
require this Court to make determinations of controlling tactual issues at
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the pleading stage. Moreover, PDX mischaracterizes the record and makes
factual misstatements in seeking protection nuder the First Amendment.
The decision ofthe Court of Appeal does not, as PDX suggests, burden
First Amendment rights or permit liability for truthful summaries of public
records. There is no First Amendment immunity for harm caused by
omitting neeessary drug wamings.
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